Joshua Bartch is Director, Chief Executive Officer, and Chairman of Mydecine Innovations Group (MIG). Mr. Bartch's entrepreneurial career took off in 2009 when he co-founded AudioTranscriptionist.com and founded the Denver-based dispensary, Doctors Orders. Following these ventures, Mr. Bartch founded a boutique investment firm that operated throughout the U.S. and Canadian markets. In 2014, Bartch co-founded Cannabase.io, the U.S.'s most significant legal and sophisticated cannabis wholesale platform. Mr. Bartch took successful exits from AudioTranscriptionist.com, Doctor’s Orders, and Cannabase.io.
Robert Roscow, M.A.
Director, Chief Scientific Officer
Robert Roscow is the Chief Scientific Officer of Mydecine. As a highly educated geneticist, he has spent his academic and professional careers looking for valuable and unique medicinal molecules found in nature. The last two companies that Mr. Roscow applied his innovations to were Canopy Growth and Ebbu, where he ran their genetics divisions. Mr. Roscow has already leveraged expertise in genomics, evolution, and molecular biology to maximize the industrial production of cannabinoids and their use in a pharmacological context. This work has resulted in multiple patent filings and accolades in publications ranging from Nature to Rolling Stone. Now, Mr. Roscow has set his focus on the vast healing potential of fungi.
Director, Chief Operations Officer
Before co-founding Mydecine Innovations Group, Mr. Michaels started consulting for various alternative start-ups around the globe, with a focus on the food, fiber, and medicinal properties of hemp and fungi. He also served as a critical principle for a leading multi-platform drug development R&D firm in Colorado called ebbu. In November of 2018, ebbu was successfully acquired by Canopy Growth for being a leader in cannabis science with a very robust IP portfolio.
Over the course of 15+ years, Mr. Michaels has held management roles within multiple unique alternative medicine companies, continuously learning and developing best practices along the way. A few career highlights outside of alternative medicine include being on the start-up team of a national action sports brand; he was one of four entrepreneurs who launched Colorado’s first sustainable glass recycling company; managed a successful events company; he was also on the business development team for a Google Ventures funded company.
Today, Mr. Michaels spends the majority of his time dedicated to developing and maintaining growth and operations at Mydecine, while advising and consulting for other like-minded companies that focus on making a positive impact.
Saeid Babaei, PhD, MBA
Dr. Babaei’s track record includes over 20 years of academic and corporate experience, during which he has led a number of novel and first-in-class product opportunities to either commercialization or to late-stage development. He brings a tremendous business foresight having closed over 25 licensing and strategic alliance transactions, as well as raising over $50 million in equity and debt financing.
Dr. Babaei is currently the Chairman and CEO of Virotek Biosciences, a Canadian biopharmaceutical engaged in R&D and commercialization of therapeutic and diagnostic solutions for infectious diseases and cancer. ViroNetix as a wholly owned subsidiary of Virotek is utilizing is mobilization platform for population screening and clinical diagnostics for COVID-19 using governmental approved PCR Testing at large scale, cost-effectively.
Prior to Virotek, Dr. Babaei founded AbCelex Technologies that had successfully developed a series of antibody-based products for infectious diseases in farm animals and food safety. Prior to that he was the VP of business development at Aptose Biosciences Inc. (formerly known as Lorus Therapeutics), where he was responsible for product and technology in- and out-licensing, strategic planning and corporate finance. During his tenure at Aptose, he successfully out-licensed a Phase III cancer immunotherapy program to a US-based biopharma, which resulted in large upfront and milestone payments as well as high double-digit tiered royalty. Prior to Lorus, Saeid served as Director, corporate and business development for Northern Therapeutics where he negotiated and executed a variety of key deal transactions, which included the out-licensing of adult stem-based gene therapy program to United Therapeutics, in-licensing of enabling technologies and the establishment of number of key R&D collaborations.
Dr. Babaei holds a PhD and an executive MBA, both from the University of Toronto. He has authored over 50 publications including research papers, conference presentations and patents. Dr. Babaei is currently a Sessional Lecturer in MBA Entrepreneurship program at Schulich Business School, York University. He is former Chairman of the Board of Directors of BriaCell Therapeutics and Vaxil Bio Ltd, both clinical stage immuno-oncology companies listed on TSX-V.
Gordon Neal has extensive experience in the metals and mining sector, capital markets, and government communications. He was most recently the Vice President of Corporate Development for Silvercorp Metals Inc., New Pacific’s largest shareholder. Before that role, he held the same position at MAG Silver Corp. Mr. Neal’s career also saw him working in the Office of the Prime Minister of Canada as a senior communications advisor. Mr. Neal is responsible for investor relations, the coordination of capital markets, and government communications.
Josephine Wu has over 18 years of hedge fund, family office, and global asset management experiences including 10 years of listed, pre IPO, and early stage Pan-Asia healthcare investment experience. She has been CIO and portfolio manager with combined assets under management over US$5 billion. She is the founder and CIO of Aionious Management Limited, a dedicated healthcare investment company which invests and provides business development and commercialization strategies in pan Asia region, specifically in China. She brings in an extensive network of experts in operation, clinical, market positioning, and regulatory knowledge in the Pan Asia healthcare landscape. Her investments in different stages of healthcare companies has led to a few successful commercialization launches of pharmaceutical products, regulatory approvals for decontamination solutions for hospitals and research centers and signing of strategic partnerships in commercialization transactions and IPOs.